| Code | CSB-RA878844MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to LAD191, targeting IL1RAP (Interleukin-1 Receptor Accessory Protein). IL1RAP functions as an essential co-receptor in IL-1 and IL-33 signaling pathways, forming heterodimeric complexes with IL-1R1 and ST2 receptors to facilitate inflammatory responses. This protein plays a critical role in innate immunity and inflammation, with dysregulated expression implicated in various pathological conditions including acute myeloid leukemia (AML), where IL1RAP is overexpressed on leukemic stem cells, as well as inflammatory disorders and certain solid tumors. The aberrant expression of IL1RAP in these diseases has positioned it as a promising therapeutic target and biomarker.
LAD191 is a well-characterized reference antibody that has been extensively utilized in cancer research, particularly in studies investigating IL1RAP as a therapeutic target in hematological malignancies. This biosimilar antibody provides researchers with a reliable tool for investigating IL1RAP biology, validating therapeutic strategies, exploring inflammatory signaling mechanisms, and advancing translational oncology studies focused on leukemia and other IL1RAP-expressing cancers.
There are currently no reviews for this product.